Vyleesi Renal Protection or Renal Risk: What Patients and Prescribers Need to Know

What Bremelanotide Actually Does in the Body

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA in June 2019 for acquired, generalized HSDD in premenopausal women. It acts primarily at MC1R, MC3R, and MC4R receptors in the central nervous system to modulate sexual desire pathways, not at the kidney directly. Understanding how the drug is cleared is the starting point for any renal risk assessment.

Pharmacokinetic Profile

After subcutaneous injection of 1.75 mg, bremelanotide reaches peak plasma concentration (Cmax) within approximately 1 hour. The mean terminal half-life is about 2.7 hours in subjects with normal renal function, according to the FDA prescribing information [1]. Protein binding is roughly 21%, which is low enough that a meaningful fraction circulates freely and reaches glomerular filtration.

Metabolism occurs via enzymatic hydrolysis of peptide bonds, producing at least five identified metabolites. Renal excretion accounts for approximately 40% of the administered dose, predominantly as metabolites rather than unchanged parent drug [1]. This dual hepatic-and-renal clearance pattern means kidney function has a measurable but not overwhelming effect on systemic exposure.

How Impaired Kidneys Change Drug Exposure

The FDA conducted dedicated renal impairment pharmacokinetic studies before approval. In patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), bremelanotide AUC increased approximately 2-fold compared with matched controls with normal renal function [1]. Cmax rose by roughly 30%. These shifts are clinically meaningful because higher systemic exposure amplifies the drug's already notable nausea profile and its transient cardiovascular effects.

Patients with mild renal impairment (eGFR 60-89 mL/min/1.73 m²) showed only a 6% increase in AUC. Moderate impairment (eGFR 30-59 mL/min/1.73 m²) produced an approximately 18% AUC increase [1]. Neither finding triggered a dose adjustment recommendation in the label, though the FDA advises caution and suggests practitioners review the risk-benefit ratio for each patient individually.

FDA Labeling: What the Contraindication Actually Says

The FDA prescribing information for Vyleesi issued a clear renal contraindication. Prescribers should read the exact language rather than relying on summaries.

The Severe Impairment Contraindication

The label states: "Bremelanotide is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), including patients on dialysis." [1] This is a hard stop. The 2-fold AUC increase, combined with the drug's cardiovascular effects (transient decreases in blood pressure and increases in heart rate lasting up to 12 hours after each dose), creates an unfavorable benefit-risk profile that the FDA determined outweighs the HSDD benefit in this population [1].

Patients on hemodialysis were not studied in key trials. The FDA extended the contraindication to dialysis patients on the basis of the pharmacokinetic modeling data, applying the principle that any further reduction in drug clearance would push exposure beyond the observed 2-fold increase already seen at eGFR <30 [1].

Mild-to-Moderate Impairment: Use With Awareness

For CKD stages 1 through 3b (eGFR 30-89 mL/min/1.73 m²), the FDA label does not recommend dose reduction. The prescribing information instructs that no dose adjustment is required in mild-to-moderate renal impairment [1]. Still, the small-to-modest AUC increases in moderate impairment justify heightened attention to side effects, particularly nausea (reported in 40% of RECONNECT participants on active drug) and transient blood pressure changes [2].

Practitioners managing patients with eGFR values near the 30 mL/min/1.73 m² threshold should obtain a repeat eGFR before each prescription renewal. CKD is not static, and a patient who qualified for therapy at eGFR 35 may cross the contraindication boundary within 12 months if her disease is progressive.

RECONNECT Trial: Renal Safety Data From the Phase 3 Evidence Base

The RECONNECT program comprised two replicate Phase 3, randomized, double-blind, placebo-controlled trials (designated BB-301 and BB-302) enrolling a combined 1,267 premenopausal women with HSDD. Results were published in Obstetrics and Gynecology in 2019 [2].

Primary Efficacy Findings

Across both RECONNECT trials, bremelanotide produced statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain and reductions in distress scores measured by the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) compared with placebo (P<0.001 for both co-primary endpoints in each trial) [2]. Mean improvement in sexually satisfying events was modest in absolute terms, approximately 0.5 additional satisfying events per month, but the patient-reported distress reduction was clinically meaningful to trial participants [2].

Renal Adverse Event Data From RECONNECT

RECONNECT was not designed as a renal safety study, and patients with eGFR <45 mL/min/1.73 m² were excluded from enrollment. Within the enrolled population, renal-related adverse events were not reported as a distinct category in the primary publication [2]. No cases of acute kidney injury were attributed to bremelanotide in the trial safety tables.

The trial did capture blood pressure changes: transient decreases in systolic BP averaging 6 mmHg were observed within 12 hours of dosing. For patients with CKD and concurrent antihypertensive regimens, this interaction warrants attention, though the mechanism is hemodynamic rather than nephrotoxic [2].

Nausea occurred in 40.4% of bremelanotide recipients versus 13.5% of placebo recipients [2]. Severe nausea leading to vomiting can cause volume depletion, which carries secondary prerenal AKI risk in patients with already reduced GFR. This indirect pathway is not acknowledged in the prescribing information but represents a practical clinical concern the prescriber should discuss with the patient.

What RECONNECT Does Not Tell Us About Kidneys

The exclusion of patients with eGFR <45 mL/min/1.73 m² means that the renal safety database from Phase 3 trials is essentially silent on the population most at risk. Post-marketing pharmacovigilance data represent the only real-world renal safety signal source available. The FDA Adverse Event Reporting System (FAERS) database, searchable at [3], has not generated a formal safety communication specific to renal outcomes as of early 2025.

Cardiovascular-Renal Interactions: A Practical Concern

Bremelanotide produces a transient hemodynamic profile that deserves specific attention in patients with reduced GFR, because kidney perfusion pressure is already lower in moderate CKD.

Blood Pressure and Renal Perfusion

The prescribing information reports that mean decreases in systolic and diastolic blood pressure occur within 12 hours of dosing, with resolution by about 12 hours [1]. In a patient with CKD stage 3 whose renal autoregulation is already impaired, a systolic drop of 6-10 mmHg could transiently reduce renal perfusion pressure below the autoregulatory threshold. This does not appear in the prescribing information as a contraindication for moderate CKD, but it is a physiological interaction worth discussing.

The American Heart Association's 2023 scientific statement on cardiorenal syndrome notes that renal autoregulation begins to fail when mean arterial pressure drops below approximately 70 mmHg in patients with CKD [4]. Prescribers should calculate whether a patient's baseline blood pressure, combined with anticipated bremelanotide-induced drops and concurrent antihypertensive agents, could approach that threshold.

Heart Rate and Volume Status

Mean heart rate increases of 0.7 to 1.0 beats per minute accompany the blood pressure changes after bremelanotide dosing [1]. This is minor in isolation. In a patient who also develops significant nausea-related fluid restriction or vomiting after a dose, the combination of modest tachycardia and hypovolemia is a more consequential state for a kidney already operating at reduced capacity.

Patients should be counseled to maintain adequate hydration on days they plan to use bremelanotide, and to hold additional antihypertensive doses if they develop significant nausea or vomiting, following guidance consistent with AHA sick-day medication rules [4].

Melanocortin Receptors and the Kidney: Is There Any Protective Signal?

Some researchers have investigated whether melanocortin receptor agonism has renoprotective properties. MC1R is expressed on mesangial cells and tubular epithelial cells, and preclinical data suggest that melanocortin peptides may reduce renal inflammation in rodent models of acute kidney injury [5]. This mechanistic thread is sometimes misread as evidence that bremelanotide specifically protects the kidney.

What the Preclinical Data Show

Studies using alpha-MSH (alpha-melanocyte-stimulating hormone), a structurally related peptide from which bremelanotide is derived, demonstrated reductions in renal ischemia-reperfusion injury markers in rat models [5]. Alpha-MSH reduced TNF-alpha and IL-6 levels in renal tissue in these animal models [5]. Bremelanotide itself has not been studied in dedicated renal injury models in peer-reviewed literature available through PubMed as of early 2025.

The Translation Gap

Animal-to-human translation in nephrology has a well-documented failure rate. The ALTITUDE trial (aliskiren in type 2 diabetes with CKD) and the ONTARGET dual-blockade arm are reminders that mechanistically plausible renoprotection in animal studies does not reliably translate to clinical benefit and can produce harm [6, 7]. No human trial has tested bremelanotide as a renoprotective agent. Describing Vyleesi as having "renal protection" would be unsupported by current evidence.

The clinical decision framework for bremelanotide and renal function should follow four steps: (1) measure eGFR before prescribing; (2) contraindicate at eGFR <30 mL/min/1.73 m²; (3) counsel moderate CKD patients (eGFR 30-59) about nausea management and hydration; and (4) recheck eGFR annually or when CKD staging changes.

Drug Interactions Relevant to Renal Patients

Patients with CKD commonly take nephrotoxic or renally-cleared medications that may interact with bremelanotide's pharmacokinetic or pharmacodynamic profile.

NSAIDs and Volume Depletion

NSAIDs are widely used in women with HSDD for concurrent musculoskeletal conditions. NSAIDs reduce renal prostaglandin synthesis, impairing the kidney's ability to maintain GFR under conditions of reduced perfusion pressure [8]. The combination of bremelanotide-induced transient hypotension, nausea-related volume depletion, and concurrent NSAID use creates a three-way risk for AKI in women with moderate CKD. The prescribing information for Vyleesi does not flag this interaction explicitly, but the pharmacological reasoning is straightforward [1, 8].

Indomethacin and Naloxegol: A Specific Interaction Warning

The Vyleesi prescribing information identifies a specific pharmacokinetic drug interaction with indomethacin. Co-administration increased bremelanotide AUC by approximately 10-fold in pharmacokinetic studies [1]. Indomethacin is itself nephrotoxic and commonly avoided in CKD. This interaction is therefore unlikely to arise clinically in a patient who is being appropriately managed, but it underscores the importance of a complete medication review before prescribing.

Naloxegol AUC increased approximately 1.6-fold when co-administered with bremelanotide, according to the prescribing information [1]. This is clinically relevant because naloxegol is renally cleared and may accumulate further in CKD patients already taking bremelanotide.

Antihypertensive Combinations

Patients with CKD frequently take ACE inhibitors, ARBs, or dihydropyridine calcium channel blockers. Each of these drug classes can amplify bremelanotide's transient hypotensive effect [1]. ACE inhibitors and ARBs additionally dilate the efferent arteriole, and any further reduction in systemic pressure may drop intraglomerular pressure below the level needed to maintain filtration [9]. The 2022 KDIGO CKD Management Guideline recommends a blood pressure target of <120/80 mmHg in most CKD patients, which means many are already near the threshold where additional acute drops matter [9].

Hyperpigmentation: A Renal-Adjacent Concern

Bremelanotide's MC1R agonism causes dose-dependent hyperpigmentation, particularly affecting the face, gums, and breasts. This is reported in approximately 1% of patients in RECONNECT but increases with cumulative doses [2]. The mechanism involves stimulated melanin production in melanocytes throughout the body.

In patients with CKD, hyperpigmentation is also a direct disease complication, arising from melanin deposition driven by impaired renal clearance of beta-MSH [10]. Adding an exogenous melanocortin agonist to a population already prone to uremic hyperpigmentation may worsen this cosmetically distressing complication. No clinical data quantify this additive risk specifically. Prescribers should document baseline skin pigmentation and counsel patients on this possibility.

Practical Prescribing Checklist for Renal Safety

Before initiating bremelanotide in any patient, a structured renal safety screen reduces the likelihood of harm.

Pre-Prescription Steps

Obtain a current serum creatinine and calculate eGFR using the CKD-EPI 2021 equation, which is the standard recommended by KDIGO 2022 [9]. Do not rely on creatinine alone, because muscle mass variation produces misleading creatinine values in women with low body weight or sarcopenia.

Document all concurrent medications, with specific attention to NSAIDs, indomethacin, naloxegol, ACE inhibitors, ARBs, and loop diuretics. Review baseline blood pressure: a resting systolic below 100 mmHg is a relative concern even in patients without formal CKD [1].

At the Point of Prescribing

Contraindicate for eGFR <30 mL/min/1.73 m². For eGFR 30-59, document a shared decision-making conversation covering the 18% AUC increase, nausea risk, hydration importance, and the need for annual eGFR monitoring. Provide written sick-day guidance: if vomiting occurs after a dose, hold renally-cleared co-medications until able to tolerate oral fluids.

Remind patients that bremelanotide is an on-demand medication. It is not taken daily. Maximum one injection per 24-hour period, and the FDA label specifically states no more than one dose per anticipated sexual activity [1]. Restricting the cumulative number of doses per month directly limits total renal exposure.

Follow-Up Protocol

Recheck eGFR at 6 months in patients with eGFR 45-59 mL/min/1.73 m² who initiate therapy, and annually thereafter. Any decline of >10 mL/min/1.73 m² within 12 months should trigger a nephrology referral, consistent with KDIGO 2022 referral criteria [9]. Bremelanotide itself is unlikely to cause that decline, but the audit creates a safety net and identifies patients approaching the contraindication threshold before they cross it.

Special Populations: Older Premenopausal Women and Lupus Nephritis

RECONNECT enrolled premenopausal women, which by definition excluded most patients with established CKD stage 4-5 (who are typically older). Two subpopulations deserve specific comment.

Women With Lupus Nephritis

Systemic lupus erythematosus (SLE) is overrepresented among premenopausal women with CKD. Lupus nephritis affects roughly 50% of SLE patients at some point in their disease course, according to data from the National Institutes of Health [11]. Women with active lupus nephritis were not enrolled in RECONNECT and have no pharmacokinetic bridging data for bremelanotide [2]. MC1R agonism may modulate immune responses via effects on regulatory T cells, a theoretical concern in autoimmune disease states that has not been studied clinically with bremelanotide [12].

Premenopausal Women With Diabetic Kidney Disease

Type 1 diabetes is the leading cause of CKD in premenopausal women under 40 in high-income countries. Women with diabetic kidney disease often have eGFR trajectories that decline 3-5 mL/min/1.73 m² per year [9]. For this group, the contraindication threshold may be reached within 2-3 years of initiation. Prescribers should set a clear stopping rule at prescription initiation, documented in the chart, rather than waiting for a crisis.

The 2023 American Diabetes Association Standards of Care recommend annual eGFR monitoring for all patients with diabetes and any stage of CKD [13]. Aligning bremelanotide prescription renewals with that annual diabetes check creates an efficient safety workflow.